1. Home
  2. HOMB vs CRSP Comparison

HOMB vs CRSP Comparison

Compare HOMB & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Home BancShares Inc.

HOMB

Home BancShares Inc.

SELL

Current Price

$29.24

Market Cap

5.7B

Sector

Finance

ML Signal

SELL

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

SELL

Current Price

$49.27

Market Cap

5.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HOMB
CRSP
Founded
1998
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
5.2B
IPO Year
2006
2016

Fundamental Metrics

Financial Performance
Metric
HOMB
CRSP
Price
$29.24
$49.27
Analyst Decision
Buy
Buy
Analyst Count
10
23
Target Price
$33.00
★ $85.63
AVG Volume (30 Days)
1.5M
★ 1.7M
Earning Date
10-14-2026
11-09-2026
Dividend Yield
★ 3.19%
N/A
EPS Growth
★ 19.90
N/A
EPS
★ 1.19
N/A
Revenue
N/A
★ $289,590,000.00
Revenue This Year
$4.24
$1,052.09
Revenue Next Year
$3.83
$273.88
P/E Ratio
$24.20
★ N/A
Revenue Growth
N/A
★ 9169.85
52 Week Low
$25.50
$44.12
52 Week High
$31.70
$75.06

Technical Indicators

Market Signals
Indicator
HOMB
CRSP
Relative Strength Index (RSI) 54.11 40.00
Support Level $29.09 $45.61
Resistance Level $29.59 $60.71
Average True Range (ATR) 0.52 2.58
MACD 0.10 -0.51
Stochastic Oscillator 86.29 5.73

Price Performance

Historical Comparison
HOMB
CRSP

About HOMB Home BancShares Inc.

Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: